Peptide Bond Formation Drives 2006 Market Surge: $1.2B in R&D, 45% CAGR for Therapeutic Peptides vs. Small Molecules
Title: Peptide Bond Formation Drives 2006 Market Surge: $1.2B in R&D, 45% CAGR for Therapeutic Peptides vs. Small Molecules Abstract: The 2006 therapeutic peptide market surge, fueled by $1.2 billion in R&D and a 45% CAGR, was driven by advances in peptide bond formation. Compared to small molecules, peptides offer superior target specificity and lower toxicity but suffer from poor oral bioavailability and metabolic instability. Key brands (e.g., GLP-1 analogs) dominate diabetes/oncology. Market trends favor long-acting formulations and solid-phase synthesis. Factory GMP certifications and purity (>95%) are critical. Logistics require cold-chain storage (-20°C). Selection criteria prioritize sequence stability, solubility, and regulatory compliance (FDA/EMA). Industry outlook remains strong, with 2026 projections exceeding $50 billion.